BAGSVAERD, Denmark — Novo Nordisk said Monday that its obesity drug semaglutide produced striking results in a late-stage study involving children as young as six, potentially opening the door to a major expansion of the GLP-1 market into a much younger population.
The company said 40.4% of children ages 6 to under 12 who received semaglutide together with lifestyle intervention were no longer classified as having obesity after 68 weeks, assuming they remained on treatment as planned.
None of the children in the placebo group reached that threshold.
Semaglutide is the active ingredient in Wegovy, Novo Nordisk’s blockbuster obesity treatment, as well as Ozempic, which is approved for diabetes.
The drug is not currently approved for children in this age group.
That makes the study commercially significant.
The global obesity-drug market has already become one of the fastest-growing areas in pharmaceuticals, driven by unprecedented demand for GLP-1 medicines from adults and adolescents.
If regulators eventually allow treatment in children under 12, the potential patient population could expand dramatically.
But the implications go well beyond market size.
Childhood obesity is linked to elevated risks of diabetes, cardiovascular disease and other long-term health problems. Physicians have traditionally relied heavily on nutrition, exercise and behavioral changes, particularly in younger children.
A medicine capable of producing substantial weight reduction would change that treatment model.
The study also raises difficult questions.
Treating children with a long-term injectable obesity drug would require physicians, parents and insurers to weigh the benefits of early intervention against questions about side effects, duration of treatment, cost and whether weight returns after therapy stops.
Those debates have already emerged around GLP-1 medicines in adults.
They could become even more intense when the patients are elementary-school-age children.
Novo Nordisk said the trial tested semaglutide alongside lifestyle modification, not as a replacement for it.
The company reported that the medicine produced significant improvements in body-mass index and other measures of weight compared with placebo.
Novo also said the safety profile was broadly consistent with what has already been observed with semaglutide in older populations.
The company will still need regulatory approval before the drug could be marketed for children under 12.
That means the results are not the same as an approval or recommendation for widespread pediatric use.
But the trial gives Novo something strategically important.
It suggests that the same drug platform that transformed adult obesity treatment may work effectively much earlier in life.
That could become especially valuable as competition in obesity medicine intensifies.
Novo Nordisk and Eli Lilly currently dominate the market, but dozens of pharmaceutical and biotechnology companies are developing competing weight-loss drugs, including pills, longer-lasting injections and new combinations designed to improve efficacy or reduce side effects.
Expanding into younger age groups could give Novo another major growth avenue.
There is also a broader economic consequence.
If GLP-1 drugs increasingly become long-term treatments beginning in childhood, healthcare systems and insurers could face enormous new spending obligations.
The drugs can cost thousands of dollars annually before rebates and discounts.
At the same time, supporters argue that effective early treatment could reduce future medical costs associated with diabetes, heart disease and other obesity-related conditions.
That leaves policymakers with a difficult calculation:
Pay more for obesity treatment now, or potentially pay much more for obesity-related disease later.
Novo Nordisk’s latest trial pushes that debate into an age group that has largely remained outside the GLP-1 boom.
And if regulators ultimately agree with the company’s findings, one of the biggest pharmaceutical markets in the world could become significantly larger.
JBizNews Desk | Bagsvaerd, Denmark
© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.
